New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompare5-Amino-1MQ vs PNC-27

5-Amino-1MQ vs PNC-27

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
5-Amino-1MQ
Immune Support
PNC-27
Summary
5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
Half-Life
Estimated 4–8 hours
Not well established; estimated minutes to hours
Admin Route
Oral
Intravenous (research), Intraperitoneal (research)
Research
Typical Dose
50–100 mg
Not established for humans; research doses vary by cell line and model
Frequency
Once to twice daily
Not established for human use
Key Benefits
  • Raises intracellular NAD+ levels
  • Directly targets adipose tissue for fat reduction
  • Reduces fat cell size and differentiation
  • Increases basal metabolic rate
  • SIRT1 activation for metabolic regulation
  • No stimulant cardiovascular side effects
  • Synergistic with intermittent fasting and caloric restriction
  • May have anti-aging metabolic benefits
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
Side Effects
  • Generally well-tolerated in available studies
  • Mild GI discomfort (rare)
  • Limited long-term human data
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
Stacks With